Eli Lilly acquired Engage Biologics Inc. in a deal valued up to $202 million in cash.

The transaction combines Engage's proprietary non-viral DNA delivery platform with Lilly's expanding genetic medicines portfolio, marking another strategic move by the pharma giant to deepen its capabilities in next-generation therapeutics.

What are the details of the deal?

Under the agreement, Lilly will acquire Engage for an undisclosed upfront cash payment plus additional payments contingent on the achievement of specified development milestones, with the total potential value reaching $202 million.¹ Financial terms beyond the milestone structure were not disclosed. Cooley LLP served as legal counsel to Engage.

What is Engage bringing to the combination?

Founded as a seed-funded startup, Engage has built its value around a potentially transformative asset: the Tethosome platform. The technology is a novel non-viral DNA delivery system engineered to address three of the field's most persistent obstacles, potency, tolerability, and the inability to re-dose patients.²

The platform works by co-formulating two components in a lipid nanoparticle: a DNA expression vector carrying a therapeutic transgene, and an mRNA strand encoding a proprietary DNA-binding protein. Once inside a target cell, the protein is translated and binds to the DNA vector, shuttling it to the nucleus while evading the innate immune sensors that have historically triggered dangerous inflammatory responses with competing approaches.² Once in the nucleus, the protein anchors the expression vector, enabling sustained, high-level gene expression without significant DNA integration or replication, a profile that distinguishes it from both viral gene therapies and earlier non-viral systems.

Early preclinical work has focused on hepatic delivery, with Engage evaluating Tethosomes in models of hemophilia A and hepatocellular carcinoma, two diseases where existing gene therapy options remain limited by immunogenicity, cytotoxicity, or short duration of effect.²

Will Olsen, co-founder and CEO of Engage, said the deal represented the next chapter for a team that had achieved rapid progress with limited resources. "We are excited to begin our next chapter with Lilly, which has demonstrated unmatched speed and a uniquely forward-thinking approach to genetic medicine," he said. "We believe that the combination of Engage's platform with Lilly's significant capabilities will meaningfully accelerate development of new genetic therapies."

Why is this deal strategically significant for Lilly?

The acquisition reflects Lilly's sustained push to build out a competitive position in genetic medicines, an area the company has identified as central to its long-term pipeline strategy.

The Tethosome platform's design, specifically its ability to achieve durable nuclear expression without integration and with reduced immune activation, addresses limitations that have constrained both viral and earlier non-viral approaches.¹ For Lilly, adding the technology at the preclinical stage offers the opportunity to shape its development trajectory and integrate it with existing internal capabilities across target discovery, manufacturing, and clinical operations.

Sources

1. Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines Engage Biologics Inc. May 20, 2026 https://www.businesswire.com/news/home/20260520932076/en/Engage-Bio-Acquired-by-Lilly-to-Accelerate-Development-of-Non-Viral-Genetic-Medicines
2. Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells National Institutes of Health Date Accessed May 20, 2026 https://reporter.nih.gov/search/0oOTZ5xDjUWJ9TdAAH8g1g/project-details/11256334